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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterised by dyspnea and loss of lung
function.
Methods: Using pooled data from the replicate, randomized, 52-week, placebo-controlled INPULSIS® trials, we
characterized the safety and tolerability of nintedanib 150 mg twice daily in patients with IPF and described how
adverse events were managed during these trials.
Results: One thousand and sixty- one patients were treated (nintedanib 638; placebo 423). Higher proportions of
patients in the nintedanib group than the placebo group had ≥1 dose reduction to 100 mg bid (27.9 % versus
3.8 %) or treatment interruption (23.7 % versus 9.9 %). Adverse events led to permanent treatment discontinuation
in 19.3 % and 13.0 % of patients in the nintedanib and placebo groups, respectively. Diarrhea was the most
frequent adverse event, reported in 62.4 % of patients in the nintedanib group versus 18.4 % in the placebo group;
however, only 4.4 % of nintedanib-treated patients discontinued trial medication prematurely due to diarrhea.
Monitoring of liver enzymes before and periodically during nintedanib treatment was recommended so that liver
enzyme elevations could be managed through dose reduction or treatment interruption.
Conclusion: Nintedanib had a manageable safety and tolerability profile in patients with IPF. Recommendations for
adverse event management minimized permanent treatment discontinuations in the INPULSIS® trials.
Trial registration: clinicaltrials.gov NCT01335464 and NCT01335477
Background
Idiopathic pulmonary fibrosis (IPF) is a progressive,
fibrosing interstitial pneumonia, occurring primarily in
the elderly population, which is characterized by increas-
ing dyspnea and loss of lung function [1–3]. Patients
with IPF have impaired quality of life and reduced exer-
cise tolerance [4]. IPF is ultimately fatal, with a median
survival time of only 2–3 years from diagnosis [3].
Our evolving understanding of the pathophysiology of
IPF suggests complex interplay between multiple path-
ways. Protein tyrosine kinases are known to play a key
role in intracellular signaling pathways involved in the
pathogenesis of lung fibrosis [5–7]. Nintedanib is an
intracellular inhibitor of tyrosine kinases, including the
receptors for the fibroblast growth factor (FGF), platelet-
derived growth factor (PDGF) and vascular endothelial
growth factor (VEGF) [8, 9]. In preclinical studies ninte-
danib interfered with processes associated with fibrosis
including fibroblast proliferation, migration and differen-
tiation and was associated with reduced secretion of
extracellular matrix and reduced lung inflammation [9].
The efficacy and safety of nintedanib as a treatment
for IPF have been studied in the Phase II, 52-week, TO-
MORROW trial [10] and in the two replicate random-
ized, placebo-controlled, 52-week Phase III INPULSIS®
trials [11, 12]. Results from the TOMORROW trial,
which involved 432 patients with IPF, suggested that
compared with placebo, treatment with nintedanib
150 mg twice daily (bid) was associated with a reduced
annual decline in forced vital capacity (FVC), fewer
acute exacerbations, and preservation of health-related
quality of life, assessed using the St George’s Respiratory
Questionnaire (SGRQ) [10]. In both INPULSIS® trials,
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the primary endpoint of the annual rate of decline in
FVC was significantly reduced by approximately 50 % in
the nintedanib group compared with placebo, consistent
with a slowing of disease progression. The adjusted an-
nual rate of decline in FVC was −114.7 mL/year with
nintedanib versus −239.9 mL/year with placebo (a differ-
ence of 125.3 mL/year [95 % confidence interval (CI):
77.7, 172.8]; p < 0.001) in INPULSIS®-1 and −113.6 mL/
year with nintedanib versus −207.3 mL/year with pla-
cebo (a difference of 93.7 mL/year [95 % CI: 44.8, 142.7];
p < 0.001) in INPULSIS®-2 [11]. In INPULSIS®-2, there
was a significant difference in favor of nintedanib for
time to first acute exacerbation and change from base-
line in SGRQ total score, both over 52 weeks. However,
in INPULSIS®-1, no significant difference between
groups was observed for either of these endpoints [11].
Gastrointestinal events, particularly diarrhea, were the
most frequently reported adverse events in patients
treated with nintedanib.
An analysis of pooled safety data from the two INPUL-
SIS® trials was pre-specified. In this manuscript, we fur-
ther characterize the safety and tolerability of nintedanib
and describe how adverse events were reported and
managed during these Phase III trials.
Methods
The INPULSIS® trials, performed at 205 sites in 24 coun-
tries in the Americas, Europe, Asia and Australia, re-
cruited a broad range of patients with IPF [11]. Patients
with IPF aged ≥40 years were eligible to participate if
they had an FVC of ≥50 % of predicted value and a dif-
fusing capacity of the lung for carbon monoxide (DLCO)
of 30–79 % of predicted value. In the absence of a surgi-
cal lung biopsy, diagnosis of IPF required the presence
of honeycombing and/or a combination of traction
bronchiectasis and reticulation, without nodules or con-
solidation, on high-resolution computed tomography
(HRCT), which was centrally reviewed. If available, sur-
gical lung biopsies were centrally reviewed to confirm
eligibility to enter the trials using a multidisciplinary ap-
proach. Patients with emphysema on HRCT were not
excluded, but patients were required to have an FEV1/
FVC ratio of ≥0.7. Concomitant therapy with prednis-
one ≤15 mg/day, or the equivalent, was permitted if the
dose had been stable for ≥8 weeks before screening.
Patients receiving other therapies for IPF, including pir-
fenidone, prednisone >15 mg/day, azathioprine, N-
acetylcysteine and any investigational treatments for
IPF, were excluded. Patients with elevated hepatic en-
zymes (alanine aminotransferase [ALT] or aspartate
aminotransferase [AST]) or bilirubin >1.5 x upper limit
of normal (ULN) were excluded.
Eligible patients were randomized using a 3:2 ratio to
receive nintedanib 150 mg bid or placebo for 52 weeks,
followed by a 4-week follow-up period. There was no re-
quirement for dose titration on initiation of treatment.
Treatment interruption and/or dose reduction from
150 mg bid to 100 mg bid were allowed for the manage-
ment of adverse events. For patients who had a dose
interruption, treatment could be reinstituted at a dose of
150 mg bid or 100 mg bid after resolution of the adverse
event. After a dose reduction, the dose could be re-
escalated to 150 mg bid. Specific recommendations were
provided to the investigators for the management of
diarrhea (Fig. 1) and hepatic enzyme elevations (Fig. 2).
For patients who had >1 treatment interruption, the
duration of treatment interruption was calculated as
total duration of all interruptions. Dose intensity was de-
fined as the amount of drug administered over the study
divided by the amount of drug that would have been re-
ceived had the 150 mg bid dose been administered
throughout the 52-week study or until discontinuation in
patients who discontinued prematurely. A pre-specified
subgroup analysis assessed the impact of dose intensity
(≤90 % versus >90 %) on the annual rate of decline in
FVC using pooled data from the two trials.
Compliance with study medication was defined as the
number of capsules taken divided by the number of cap-
sules that should have been taken over the trial period.
Safety was assessed by means of clinical and laboratory
evaluation, clinical assessment of vital signs and physical
examination at study visits and the recording of adverse
Fig. 1 Algorithm for the management of diarrhea adverse events in the INPULSIS® trials. i.v., intravenous
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events, coded according to the Medical Dictionary for
Regulatory Activities (MedDRA) version 16.1. The ana-
lyses were descriptive and based on patients who re-
ceived ≥1 dose of study medication. Patients with
adverse events with onset after the first dose and up to
28 days after the last dose of trial medication were in-
cluded in the analysis. The intensity of adverse events
was rated by the investigators as mild (easily tolerated),
moderate (enough discomfort to cause interference with
usual activity) or severe (incapacitating or causing inability
to work or to perform usual activities). For every adverse
event, investigators reported whether they considered the
event was related to study drug. For patients who experi-
enced ≥1 diarrhea adverse event, the duration of diarrhea
adverse events was calculated as the total duration of all
the events. A specific diarrhea electronic case report form
(eCRF) was introduced during the course of the trials to
characterize diarrhea adverse events. Routine clinical la-
boratory testing was undertaken at screening and weeks 2,
4, 6, 12, 18, 24, 30, 36, 44 and 52.
Both trials were conducted in accordance with the
principles of the Declaration of Helsinki and the Harmo-
nised Tripartite Guideline for Good Clinical Practice
from the International Conference on Harmonisation
and were approved by local authorities. The clinical
protocol was approved by an independent ethics com-
mittee or institutional review board at each participating




A total of 1061 patients were treated in the two INPUL-
SIS® trials, 638 in the nintedanib group and 423 in the
placebo group. Demographics and baseline characteris-
tics were comparable between the treatment groups
(Table 1 and Additional file 1).
Exposure
The mean (standard deviation [SD]) duration of expos-
ure was 10.3 (3.4) months in the nintedanib group and
10.8 (2.8) months in the placebo group. Compliance
with study medication was 96.4 % in the nintedanib
group and 96.7 % in the placebo group.
A summary of the proportion of patients requiring
dose reductions and treatment interruptions is presented
Fig. 2 Algorithm for the management of hepatic enzyme elevations in the INPULSIS® trials. *Defined as increase in hepatic transaminases (AST or
ALT) to ≥3 x ULN, and i) total bilirubin >1.5 ULN or ii) INR >1.5 or iii) appearance of fatigue, nausea, vomiting, right upper abdominal quadrant
pain or tenderness, fever, rash and/or eosinophilia (>5%). In the INPULSIS® trials, routine clinical laboratory testing was undertaken at screening
and weeks 2, 4, 6, 12, 18, 24, 30, 36, 44 and 52
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in Table 2. The proportion of patients who had ≥1 dose
reduction from 150 mg bid to 100 mg bid was higher in
the nintedanib group than in the placebo group (178 pa-
tients [27.9 %] versus 16 patients [3.8 %]); 15 patients
(2.4 %) in the nintedanib group and none in the placebo
group had ≥2 dose reductions from 150 mg bid to
100 mg bid. There was no distinct temporal pattern as-
sociated with dose reductions. Forty patients (6.3 %) in
the nintedanib group and 7 patients (1.7 %) in the pla-
cebo group had ≥1 dose increase from 100 mg bid to
150 mg bid. In total, 76.3 % of patients in the nintedanib
group and 97.9 % of patients in the placebo group re-
ceived 150 mg bid as their last dose.
A greater proportion of patients treated with ninteda-
nib had ≥1 treatment interruption than those treated
with placebo (23.7 % versus 9.9 %); 38 patients (6.0 %) in
the nintedanib group and 3 patients (0.7 %) in the pla-
cebo group had ≥2 treatment interruptions. There was
no discernible accumulation of dose interruptions during
a specific time period during the trials. The mean (SD)
duration of interruption was 25.1 (18.8) and 25.6 (15.3)
days in the nintedanib and placebo groups, respectively.
Table 1 Baseline demographics and clinical characteristics in
the INPULSIS® trials
Nintedanib Placebo
(n = 638) (n = 423)
Male, n (%) 507 (79.5) 334 (79.0)
Age, years, mean (SD) 66.6 (8.1) 67.0 (7.9)
Weight, kg, mean (SD) 79.2 (16.6) 78.6 (16.5)
Race, n (%)
White 360 (56.4) 248 (58.6)
Asian 194 (30.4) 128 (30.3)
Black 2 (0.3) 0 (0.0)
Missinga 82 (12.9) 47 (11.1)
Smoking status, n (%)
Never smoked 174 (27.3) 122 (28.8)
Ex-smoker 435 (68.2) 283 (66.9)
Current smoker 29 (4.5) 18 (4.3)
Time since diagnosis of IPF, years, mean (SD)b 1.7 (1.4) 1.6 (1.3)
FVC, mL, mean (SD) 2714 (757) 2728 (810)
FVC, % predicted, mean (SD) 79.7 (17.6) 79.3 (18.2)
FEV1/FVC ratio, %, mean (SD) 81.7 (5.8) 81.7 (6.0)
DLCO, % predicted, mean (SD) 47.4 (13.5) 47.0 (13.4)
SpO2, %, mean (SD) 95.9 (2.3) 95.8 (2.0)
SGRQ total score, mean (SD)c 39.5 (19.2) 39.6 (18.5)
Based on patients who received ≥1 dose of study medication. Data collected
at screening unless otherwise stated
aIt was not permitted to collect data on race in France
bAt randomization
cn = 624 for nintedanib 150 mg bid and n = 419 for placebo
Table 2 Dose reductions and treatment interruptions in the
INPULSIS® trials
N (%) Nintedanib Placebo
(n = 638) (n = 423)
Dose reductions
Patients with ≥1 dose reduction 178 (27.9) 16 (3.8)
Dose reductions per patient
1 163 (25.5) 16 (3.8)
2 13 (2.0) 0 (0.0)
> 2 2 (0.3) 0 (0.0)
Time to first dose reduction
≤ 1 month 20 (3.1) 1 (0.2)
> 1 month to ≤2 months 28 (4.4) 4 (0.9)
> 2 month to ≤3 months 19 (3.0) 0 (0.0)
> 3 month to ≤4 months 18 (2.8) 3 (0.7)
> 4 month to ≤5 months 24 (3.8) 1 (0.2)
> 5 month to ≤6 months 22 (3.4) 1 (0.2)
> 6 months 47 (7.4) 6 (1.4)
Patients with ≥1 dose increase to
150 mg bid
40 (6.3) 7 (1.7)
Patients who took 150 mg bid
as last dose
487 (76.3) 414 (97.9)
Treatment interruptions
Patients with ≥1 treatment
interruption
151 (23.7) 42 (9.9)
Treatment interruptions per patient
1 113 (17.7) 39 (9.2)
2 30 (4.7) 3 (0.7)
> 2 8 (1.3) 0 (0.0)
Time to first treatment interruption
≤ 1 month 32 (5.0) 3 (0.7)
> 1 month to ≤2 months 18 (2.8) 4 (0.9)
> 2 month to ≤3 months 18 (2.8) 6 (1.4)
> 3 month to ≤4 months 21 (3.3) 4 (0.9)
> 4 month to ≤5 months 18 (2.8) 2 (0.5)
> 5 month to ≤6 months 11 (1.7) 3 (0.7)
> 6 months 33 (5.2) 20 (4.7)
Patients re-introduced at the same
dose of 100 mg bid after treatment
interruptiona
20 (13.2) 1 (2.4)
Patients re-introduced at a reduced
dose of 100 mg bid after treatment
interruptiona
81 (53.6) 9 (21.4)
Patients re-introduced at the same
dose of 150 mg bid after treatment
interruptiona
49 (32.5) 32 (76.2)
Patients re-introduced at an increased
dose of 150 mg bid after treatment
interruptiona
1 (0.7) 0 (0.0)
Based on patients who received ≥1 dose of study medication
aDose at last re-introduction
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In total, 24.5 % of patients in the nintedanib group
and 18.9 % in the placebo group prematurely discontin-
ued trial medication; 19.3 % and 13.0 % of patients
treated with nintedanib and placebo, respectively, pre-
maturely discontinued trial medication due to an adverse
event.
Mean dose intensity was high in both treatment groups.
In the subgroup of patients with dose intensity >90 %
(n = 484), mean (SD) dose intensity was 99.3 (2.2) % in
patients treated with nintedanib and 99.8 (1.6) % in pa-
tients treated with placebo. In the subgroup of patients
with dose intensity ≤90 % (n = 154), mean (SD) dose in-
tensity was 76.1 (10.1) % in patients treated with ninte-
danib and 80.5 (7.5) % in patients treated with placebo.
The adjusted annual rate of decline in FVC was of simi-
lar magnitude in patients treated with nintedanib with
dose intensity >90 % as in patients treated with ninte-
danib with dose intensity ≤90 % (mean [standard error]
112.7 [12.8] and 72.7 [24.3] ml/year, respectively).
Adverse events
A summary of adverse events is presented in Table 3. In
total, 95.5 % of patients treated with nintedanib and
89.6 % of patients treated with placebo experienced ≥1
adverse event. The proportion of patients who had ≥1
serious adverse event was similar between the ninteda-
nib (30.4 %) and placebo (30.0 %) groups.
Diarrhea was the most frequently reported adverse
event in the nintedanib group, reported in 62.4 % of pa-
tients compared with 18.4 % of patients in the placebo
group. A summary of diarrhea adverse events and their
clinical consequences is presented in Table 4. Almost all
patients who reported diarrhea adverse events (ninteda-
nib: 94.5 %, placebo: 97.4 %) reported events of mild or
moderate intensity. Of patients who had ≥1 completed
eCRF specific for diarrhea (n = 185 in the nintedanib
group; n = 25 in the placebo group), most had <4 extra
stools per day (nintedanib: 111 patients [60.0 %], pla-
cebo: 19 patients [76.0 %]). Bowel movements were most
commonly characterized as watery with or without
formed stool. Among patients who experienced a diar-
rhea adverse event, anti-diarrheal therapies (most com-
monly loperamide) were used by 55.3 % of patients in
the nintedanib group and 25.6 % of patients in the pla-
cebo group during the on-treatment period. For most
patients who reported diarrhea adverse events (ninteda-
nib: 78.6 %, placebo: 98.7 %), the events resolved without
the need for dose reduction or treatment interruption. A
small proportion of patients had a permanent dose re-
duction (nintedanib: 68 patients [10.7 %], placebo: no
patients) and/or discontinued trial medication prema-
turely due to diarrhea (nintedanib: 28 patients [4.4 %],
placebo: 1 [0.2 %]). Among patients who experienced
any diarrhea adverse events, most reported a single
Table 3 Patients with adverse events in the INPULSIS® trials
N (%) Nintedanib Placebo
(n = 638) (n = 423)
Any adverse event(s) 609 (95.5) 379 (89.6)
Most frequent adverse eventsa
Diarrhea 398 (62.4) 78 (18.4)
Nausea 156 (24.5) 28 (6.6)
Nasopharyngitis 87 (13.6) 68 (16.1)
Cough 85 (13.3) 57 (13.5)
Progression of idiopathic
pulmonary fibrosisb
64 (10.0) 61 (14.4)
Bronchitis 67 (10.5) 45 (10.6)
Dyspnea 49 (7.7) 48 (11.3)
Decreased appetite 68 (10.7) 24 (5.7)
Vomiting 74 (11.6) 11 (2.6)
Adverse event(s) leading to
permanent dose reduction
101 (15.8) 2 (0.5)
Adverse event(s) leading to
permanent treatment discontinuation
123 (19.3) 55 (13.0)
Adverse events that most frequently
led to permanent treatment
discontinuationc
Progression of idiopathic pulmonary
fibrosisb
13 (2.0) 21 (5.0)
Diarrhea 28 (4.4) 1 (0.2)
Nausea 13 (2.0) 0 (0.0)
Decreased appetite 9 (1.4) 1 (0.2)
Pneumonia 6 (0.9) 1 (0.2)
Weight decreased 6 (0.9) 1 (0.2)
Abdominal pain 5 (0.8) 1 (0.2)
Vomiting 5 (0.8) 0 (0.0)
Asthenia 4 (0.6) 0 (0.0)
Increased alanine aminotransferase 4 (0.6) 0 (0.0)
Drug-related adverse events (as reported
by the investigators)
455 (71.3) 120 (28.4)
Severe adverse eventsd 174 (27.3) 99 (23.4)
Serious adverse eventse 194 (30.4) 127 (30.0)
Fatal adverse event(s) 37 (5.8) 31 (7.3)
Based on patients who received ≥1 dose of study medication
aAdverse events reported in >10 % of patients in either treatment group
bCorresponds to the MedDRA term ‘IPF’, which included disease worsening
and IPF exacerbations
cAdverse events leading to permanent treatment discontinuation in >0.5 % of
patients in either treatment group, by preferred term
dA severe adverse event was related to intensity and was defined as an event
that was incapacitating or that caused an inability to work or to perform
usual activities
eA serious adverse event was defined as any adverse event that resulted in
death, was immediately life-threatening, resulted in persistent or clinically
significant disability or incapacity, required or prolonged hospitalization, was
related to a congenital anomaly or birth defect or was deemed serious for any
other reason
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event (nintedanib: 60.3 %; placebo: 76.9 %) or 2 events
(nintedanib: 26.4 %; placebo: 15.4 %). The median (mini-
mum, maximum) duration of diarrhea events was 138.5
(1, 473) days in the nintedanib group and 7.0 (1, 453)
days in the placebo group. For most patients with a diar-
rhea adverse event, the first onset occurred within the
first 3 months of treatment (Fig. 3).
In a post-hoc analysis, the absolute mean (SD) change
from baseline in FVC at week 52 was −67.7 (271.4) ml
for nintedanib-treated patients who experienced ≥1 diar-
rhea adverse event (n = 398) and −129.4 (246.0) ml for
nintedanib-treated patients without any diarrhea events
(n = 240). For patients treated with placebo, the abso-
lute mean (SD) change from baseline in FVC at week
52 was −227.7 (283.6) ml for patients who experienced ≥1
diarrhea adverse event (n = 78) and −197.3 (294.7) ml for
patients without any diarrhea events (n = 345).
A summary of nausea and vomiting adverse events is
presented in Table 4. Almost all nausea and vomiting ad-
verse events were mild or moderate in intensity. Most
patients who experienced nausea reported only 1 event
(nintedanib: 74.4 %; placebo: 96.4 %). Similarly, most pa-
tients who experienced vomiting reported only 1 event
(nintedanib: 54 patients [73.0 %], placebo: 11 patients
[100 %]). The majority of nausea adverse events had an
early onset; vomiting adverse events occurred at any
time relative to the start of treatment.
A summary of the proportions of patients with elevations
in hepatic enzymes is shown in Table 5. For ALT, AST and
bilirubin, the proportion of patients who had normal values
at baseline but maximum values above the ULN during
treatment was higher in the nintedanib group than in the
placebo group. In the majority of patients, values had
returned to values within the normal range by the end of
treatment. Nevertheless, a greater proportion of patients in
the nintedanib group than in the placebo group had a last
value on treatment above the ULN for ALT (4.4 % versus
3.4 %) and AST (5.0 % versus 1.7 %). While it is difficult to
identify a pattern due to the low number of patients with
ALT and/or AST elevations ≥3x ULN, the elevations
Table 4 Gastrointestinal adverse events and clinical consequences in the INPULSIS® trials
Diarrhea Nausea Vomiting
Nintedanib Placebo Nintedanib Placebo Nintedanib Placebo
(n = 398) (n = 78) (n = 156) (n = 28) (n = 74) (n = 11)
Intensity of adverse eventa
Mild 226 (56.8) 60 (76.9) 116 (74.4) 26 (92.9) 49 (66.2) 9 (81.8)
Moderate 150 (37.7) 16 (20.5) 38 (24.4) 2 (7.1) 21 (28.4) 2 (18.2)
Severe 21 (5.3) 2 (2.6) 2 (1.3) 0 (0.0) 4 (5.4) 0 (0.0)
Outcome of adverse eventa
Recovered 350 (87.9) 72 (92.3) 143 (91.7) 22 (78.6) 69 (93.2) 11 (100.0)
Not yet recoveredb 43 (10.8) 6 (7.7) 12 (7.7) 6 (21.4) 5 (6.8) 0 (0.0)
Fatal 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Unknown 5 (1.3) 0 (0.0) 1 (0.6) 0 (0.0) 0 (0.0) 0 (0.0)
Consequence for dosingc
No permanent dose reduction or discontinuationd 313 (78.6) 77 (98.7) 135 (86.5) 28 (100.0) 64 (86.5) 11 (100.0)
Permanent dose reduction of trial drug 57 (14.3) 0 (0.0) 8 (5.1) 0 (0.0) 5 (6.8) 0 (0.0)
Permanent discontinuation of trial drug 28 (7.0) 1 (1.3) 13 (8.3) 0 (0.0) 5 (6.8) 0 (0.0)
Number of adverse events
1 240 (60.3) 60 (76.9) 116 (74.4) 27 (96.4) 54 (73.0) 11 (100.0)
2 105 (26.4) 12 (15.4) 31 (19.9) 1 (3.6) 14 (18.9) 0 (0.0)
3 29 (7.3) 3 (3.8) 8 (5.1) 0 (0.0) 4 (5.4) 0 (0.0)
≥ 4 24 (6.0) 3 (3.8) 1 (0.6) 0 (0.0) 2 (2.7) 0 (0.0)
Duration of events, days, median (minimum, maximum)e 138.5 (1, 473) 7.0 (1, 453) 44.0 (1, 400) 51.0 (1, 404) 6.0 (1, 390) 1.0 (1, 4)
Data are N (%) of patients with ≥1 diarrhea or nausea or vomiting adverse events unless otherwise stated
aFor patients with more with one event, the intensity/outcome of the worst event is displayed
bThe patient has not yet returned to his/her previous health status, continues to be followed for the adverse event, but is expected to recover without sequelae
cFor patients with more than one event, the last consequence for dosing is displayed
dIncludes patients with temporary dose reductions or treatment interruptions
eFor patients who experienced ≥1 adverse event, the duration of adverse events was calculated as the total duration of all the events; the definition of a single
event was not specified to the investigators in the trial protocol
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appeared not to occur at a particular time relative to the
start of treatment. Thirty-two patients (5.0 %) in the ninte-
danib group and 3 patients (0.7 %) in the placebo group
had ALT and/or AST elevations ≥3x ULN. Hy’s law criteria
were met in 1 patient (in the placebo group).
With regards to other adverse events of interest, bleed-
ing events were reported in 10.3 % of patients in the
nintedanib group and 7.8 % of patients in the placebo
group. Epistaxis, which occurred in 26 patients (4.1 %)
in the nintedanib group and 13 (3.1 %) in the placebo
group and contusion, which occurred in 10 patients
(1.6 %) in the nintedanib group and 4 (0.9 %) in the pla-
cebo group, were the most frequently reported bleeding
events. Serious bleeding events occurred with similar in-
cidences in both treatment groups (8 patients [1.3 %] in
the nintedanib group and 6 [1.4 %] in the placebo group.
Gastrointestinal perforation was reported in 2 patients
(0.3 %) in the nintedanib group and no patients in the
placebo group. Hypertension was reported in 33 patients
(5.2 %) in the nintedanib group and 17 (4.0 %) in the
placebo group.
Cardiac disorder adverse events were reported in
10.0 % of patients treated with nintedanib and 10.6 % of
patients treated with placebo (Additional file 2). Serious
cardiac disorder adverse events were reported in 5.0 %
of patients in the nintedanib group and 5.4 % of patients
in the placebo group; fatal cardiac disorders occurred in
3 patients (0.5 %) and 6 patients (1.4 %) in the ninteda-
nib and placebo groups, respectively. The MedDRA cat-
egory of ‘ischemic heart disease’ was reported in a
similar proportion of patients in the nintedanib (4.2 %)
and placebo (4.0 %) groups (Additional file 2). Within
the MedDRA category of ‘ischemic heart disease’, a
higher proportion of patients reported an event in the
Table 5 Hepatic enzyme elevation adverse events in the
INPULSIS® trials
N (%) Nintedanib Placebo
(n = 638) (n = 423)
Elevations in ALT and/or AST
≥ 3x ULN 32 (5.0) 3 (0.7)
≥ 5x ULN 14 (2.2) 1 (0.2)
≥ 8x ULN 5 (0.8) 1 (0.2)
Elevations in maximum total bilirubin
≥ 1.5x ULN 15 (2.4) 3 (0.7)
≥ 2x ULN 3 (0.5) 2 (0.5)
Elevations in maximum alkaline phosphatase
≥ 1.5x ULN 37 (5.8) 4 (0.9)
≥ 2x ULN 17 (2.7) 1 (0.2)
Normal ALT values at baseline but maximum
value on treatment > ULN on treatmenta
169 (27.3) 30 (7.2)
Normal AST values at baseline but maximum
value on treatment > ULNb
134 (21.4) 22 (5.3)
Normal bilirubin values at baseline but maximum
value on treatment > ULNc
48 (7.7) 22 (5.3)
Normal alkaline phosphatase values at baseline
but maximum value on treatment > ULNd
94 (15.3) 28 (6.8)
Based on patients who received ≥1 dose of study medication. Categories
are cumulative
anintedanib n = 620, placebo n = 416; bnintedanib n = 625, placebo n = 418;
cnintedanib n = 621, placebo n = 413; dnintedanib n = 615, placebo n = 412
Hy’s law criteria were met in no patients in the nintedanib group and in 1
patient in the placebo group. Hy’s law criteria: AST or ALT ≥3x ULN and total
bilirubin ≥2x ULN measured in the same blood sample, and no other reason
found to explain the combination of increased hepatic transaminases and
bilirubin, such as viral hepatitis A, B or C; pre-existing or acute hepatic disease;
or the use of another drug capable of causing the observed injury
Fig. 3 Time to first diarrhea adverse event in the INPULSIS® trials
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subcategory ‘myocardial infarction’ in the nintedanib
group (17 patients [2.7 %]) compared with the placebo
group (5 patients [1.2 %]), but a lower proportion of pa-
tients reported an event in the other subcategory, ‘other
ischemic heart disease’, in the nintedanib group (11 pa-
tients [1.7 %]) than in the placebo group (13 patients
([3.1 %]) (Additional file 2). The MedDRA preferred
terms of myocardial infarction or acute myocardial in-
farction were reported in 10 patients (1.6 %) treated with
nintedanib and 2 patients (0.5 %) treated with placebo.
A higher proportion of patients experienced weight
loss as an adverse event in the nintedanib group (9.7 %)
than in the placebo group (3.5 %). The mean change
from baseline in body weight at week 52 was −3.1 kg in
the nintedanib group and −1.4 kg in the placebo group.
The proportion of patients with infection adverse events
was similar in both treatment groups (nintedanib:
56.3 %; placebo: 53.9 %) as was the proportion of pa-
tients with adverse events related to respiratory, thoracic
and mediastinal disorders (nintedanib: 39.8 %; placebo:
41.8 %).
Discussion
We report collective safety data for nintedanib from the
two Phase III INPULSIS® trials. These data demonstrate
that nintedanib has a manageable safety and tolerability
profile in patients with IPF.
In the INPULSIS® trials, the investigators were pro-
vided with recommendations for the management of ad-
verse events, including symptomatic measures as well as
the option of a flexible dosing regimen. These recom-
mendations provide guidance for the management of ad-
verse events associated with the use of nintedanib in
clinical practice. Although a greater proportion of pa-
tients in the nintedanib group had a dose reduction or
treatment interruption compared with patients in the
placebo group, mean dose intensity in the nintedanib
group was high. A pre-specified subgroup analysis dem-
onstrated that nintedanib reduced FVC decline both in
patients with a dose intensity of ≤90 % and in patients
with a dose intensity >90 %, suggesting that dose reduc-
tions or treatment interruptions made to manage ad-
verse events had no major impact on the efficacy of
nintedanib.
As expected based on data from previous studies in
patients with IPF [10] and patients with solid tumors
[13, 14], the most frequently reported adverse events in
patients treated with nintedanib in the INPULSIS® trials
were gastrointestinal in nature, particularly diarrhea,
nausea, vomiting and decreased appetite. Almost all
such adverse events were mild or moderate in intensity
and most resolved without the need for dose reduction
or treatment interruption. A limitation of our studies
was that the definition of a single diarrhea event was not
specified to the investigators in the trial protocol. Thus,
for patients with intermittent diarrhea over a prolonged
period, some investigators may have reported this as sev-
eral events and others as a single event, reducing the
precision of our estimate of the number and the dur-
ation of diarrhea events. Only 4.4 % of patients in the
nintedanib group discontinued trial medication prema-
turely due to diarrhea, suggesting that recommendations
for the management of diarrhea, including symptomatic
treatment with anti-diarrheal therapies, were successful
in minimizing permanent treatment discontinuations.
However, only 55.3 % of patients treated with nintedanib
who experienced a diarrhea adverse event received
symptomatic anti-diarrheal treatment during the on-
treatment period, indicating that there is a need to
provide adequate information to physicians in clinical
practice and patients about the early management of
diarrhea to enable patients to continue taking the drug
and so receive maximum benefit from nintedanib treat-
ment. This also applies to anti-emetic treatments. It is
recommended that patients treated with nintedanib who
experience diarrhea should maintain hydration and take
antidiarrheal therapy (e.g., loperamide) as soon as symp-
toms occur. Dose reduction from 150 mg bid to 100 mg
bid or temporary treatment interruption can also be
considered. If diarrhea persists, nintedanib should be
discontinued. The exact mechanism by which tyrosine
kinase inhibition causes nausea or diarrhea is unknown;
however, VEGF and VEGF receptors (VEGFR) are
known to be highly expressed in the endocrine glands,
stomach and intestines, suggesting that VEGF inhibition
may cause morphometric changes in the bowel mucosa
[15, 16]. A post-hoc analysis of data from the INPULSIS®
trials showed that nintedanib was effective both in pa-
tients who had ≥1 diarrhea adverse event and patients
who had no diarrhea adverse events, with a lower mean
decline in FVC in patients who had ≥1 diarrhea adverse
event. Although the limitations of this descriptive ana-
lysis do not allow firm conclusions to be drawn regard-
ing the lower mean decline in FVC in patients who had
diarrhea, trials investigating the use of tyrosine kinase
inhibitors in oncology have reported an association
between drug-related adverse events such as rash and
diarrhea and efficacy [17, 18].
In addition to diarrhea, adverse events associated with
inhibition of VEGF or VEGFR include arterial hyperten-
sion, gastrointestinal perforations, thromboembolism
and bleeding [19, 20] and therefore these are potential
risks of nintedanib treatment. Patients treated with full-
dose anticoagulation or at known risk for bleeding were
excluded from the INPULSIS® studies. This has led to
recommendations stating that patients at known risk for
bleeding should be treated with nintedanib only if the
anticipated benefit outweighs the potential risk.
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The mechanism behind the elevations in hepatic en-
zymes or bilirubin following treatment with nintedanib
is not well understood, but requires laboratory testing
before and periodically during treatment (e.g., during
regular patient visits). In general, elevations in hepatic
enzymes and total bilirubin were uncommon and
returned to normal following dose reduction or treat-
ment interruption.
Although cardiac disorders adverse events were bal-
anced between the nintedanib and placebo groups, a
higher proportion of patients in the nintedanib groups
had myocardial infarctions. Conversely, a lower propor-
tion of patients in the nintedanib groups had other is-
chemic heart disease. The clinical significance of this
finding is unknown, and further observation is needed.
However, it should be noted that the prevalence of myo-
cardial infarctions in the INPULSIS® trials was low and
below that observed in patients with IPF based on data
from two US health claims databases [21].
In conclusion, pooled safety data from the INPULSIS®
trials demonstrate that the dosing regimen utilized and
the recommendations given for the management of ad-
verse events, including symptomatic measures and hep-
atic enzyme monitoring, were successful in minimizing
permanent treatment discontinuations. Nintedanib had a
manageable safety and tolerability profile in patients
with IPF. Physicians, nurses and patients will benefit
from clear instructions on how to monitor patients and
manage adverse events that may be associated with
treatment with nintedanib, consistent with those imple-
mented in the INPULSIS® trials.
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